VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q57661894  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000330.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q57661894‏
024 ‎‡a  0000-0002-3156-3418‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q57661894‏
100 0 ‎‡a  Philip Robinson‏ ‎‡9  eo‏ ‎‡9  co‏ ‎‡9  io‏ ‎‡9  af‏ ‎‡9  vmf‏ ‎‡9  vi‏ ‎‡9  ca‏ ‎‡9  it‏ ‎‡9  an‏ ‎‡9  eu‏ ‎‡9  cy‏ ‎‡9  gd‏ ‎‡9  pt-br‏ ‎‡9  ga‏ ‎‡9  zu‏ ‎‡9  cs‏ ‎‡9  et‏ ‎‡9  gl‏ ‎‡9  ie‏ ‎‡9  id‏ ‎‡9  es‏ ‎‡9  en-gb‏ ‎‡9  lb‏ ‎‡9  wa‏ ‎‡9  nn‏ ‎‡9  min‏ ‎‡9  nb‏ ‎‡9  pms‏ ‎‡9  nap‏ ‎‡9  lij‏ ‎‡9  li‏ ‎‡9  wo‏ ‎‡9  lt‏ ‎‡9  frp‏ ‎‡9  sw‏ ‎‡9  nds-nl‏ ‎‡9  rm‏ ‎‡9  ro‏ ‎‡9  ia‏ ‎‡9  sr-el‏ ‎‡9  pcd‏ ‎‡9  vec‏ ‎‡9  kab‏ ‎‡9  sco‏ ‎‡9  nrm‏ ‎‡9  hr‏ ‎‡9  bm‏ ‎‡9  de‏ ‎‡9  hu‏ ‎‡9  da‏ ‎‡9  fr‏ ‎‡9  prg‏ ‎‡9  br‏ ‎‡9  fi‏ ‎‡9  vls‏ ‎‡9  vo‏ ‎‡9  kg‏ ‎‡9  en-ca‏ ‎‡9  scn‏ ‎‡9  jam‏ ‎‡9  mg‏ ‎‡9  bar‏ ‎‡9  pt‏ ‎‡9  gsw‏ ‎‡9  sc‏ ‎‡9  fur‏ ‎‡9  mi‏ ‎‡9  sv‏ ‎‡9  de-ch‏ ‎‡9  frc‏ ‎‡9  sk‏ ‎‡9  pap‏ ‎‡9  oc‏ ‎‡9  ms‏ ‎‡9  de-at‏ ‎‡9  nds‏ ‎‡9  rgn‏ ‎‡9  pl‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Philip C Robinson‏ ‎‡9  ast‏
400 0 ‎‡a  ফিলিপ সি রবিনসন‏ ‎‡9  bn‏
400 0 ‎‡a  Philip Robinson‏ ‎‡c  New Zealand rheumatologist‏ ‎‡9  en‏
400 0 ‎‡a  Philip C Robinson‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
400 0 ‎‡a  Philip Robinson‏ ‎‡c  araştırmacı‏ ‎‡9  tr‏
670 ‎‡a  Author's A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic‏
670 ‎‡a  Author's A qualitative and quantitative analysis of the characteristics of gout patient education resources‏
670 ‎‡a  Author's A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections‏
670 ‎‡a  Author's Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment‏
670 ‎‡a  Author's Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.‏
670 ‎‡a  Author's Advances in pharmacotherapy for the treatment of gout‏
670 ‎‡a  Author's Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials‏
670 ‎‡a  Author's An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population‏
670 ‎‡a  Author's Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital.‏
670 ‎‡a  Author's Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin‏
670 ‎‡a  Author's Author reply‏
670 ‎‡a  Author's Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis‏
670 ‎‡a  Author's Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19‏
670 ‎‡a  Author's Biologic therapy for uveitis: addressing access issues is paramount‏
670 ‎‡a  Author's Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis‏
670 ‎‡a  Author's Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry‏
670 ‎‡a  Author's Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis‏
670 ‎‡a  Author's Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol is Very Cost Effective‏
670 ‎‡a  Author's Conducting research in a pandemic: The power of social media‏
670 ‎‡a  Author's Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).‏
670 ‎‡a  Author's Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand.‏
670 ‎‡a  Author's Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation‏
670 ‎‡a  Author's COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from‏
670 ‎‡a  Author's COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations‏
670 ‎‡a  Author's Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis‏
670 ‎‡a  Author's Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis‏
670 ‎‡a  Author's Does midlife obesity really lower dementia risk?‏
670 ‎‡a  Author's Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis.‏
670 ‎‡a  Author's Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases‏
670 ‎‡a  Author's Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site‏
670 ‎‡a  Author's ERAP1 biology and assessment in Ankylosing Spondylitis.‏
670 ‎‡a  Author's ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers‏
670 ‎‡a  Author's ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients‏
670 ‎‡a  Author's Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study‏
670 ‎‡a  Author's Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease‏
670 ‎‡a  Author's Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry‏
670 ‎‡a  Author's Febuxostat for the treatment of hyperuricaemia in gout‏
670 ‎‡a  Author's Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist‏
670 ‎‡a  Author's Genetic diagnostic profiling in axial spondyloarthritis: a real world study‏
670 ‎‡a  Author's Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis‏
670 ‎‡a  Author's Genetics of ankylosing spondylitis‏
670 ‎‡a  Author's Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci‏
670 ‎‡a  Author's Giant cell arteritis and COVID-19: similarities and discriminators, a systematic literature review‏
670 ‎‡a  Author's Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance‏
670 ‎‡a  Author's Gout - An update of aetiology, genetics, co-morbidities and management‏
670 ‎‡a  Author's Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout‏
670 ‎‡a  Author's Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout‏
670 ‎‡a  Author's Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.‏
670 ‎‡a  Author's Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank‏
670 ‎‡a  Author's Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.‏
670 ‎‡a  Author's Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci‏
670 ‎‡a  Author's Insight into rheumatological cause and effect through the use of Mendelian randomization‏
670 ‎‡a  Author's Lesinurad for the treatment of hyperuricaemia in people with gout‏
670 ‎‡a  Author's Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.‏
670 ‎‡a  Author's Management of autoimmune disease during the COVID-19 pandemic‏
670 ‎‡a  Author's Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia‏
670 ‎‡a  Author's Never too old for an inherited condition‏
670 ‎‡a  Author's Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy‏
670 ‎‡a  Author's Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes‏
670 ‎‡a  Author's Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinic‏
670 ‎‡a  Author's Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department‏
670 ‎‡a  Author's Predictors of Success in Gout Treatment‏
670 ‎‡a  Author's Race/ethnicity association with COVID-19 outcomes in rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician Registry‏
670 ‎‡a  Author's Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al‏
670 ‎‡a  Author's Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-repor‏
670 ‎‡a  Author's Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries‏
670 ‎‡a  Author's Role of genetics in infection-associated arthritis‏
670 ‎‡a  Author's Rothia aeria as a cause of sepsis in a native joint‏
670 ‎‡a  Author's SARS CoV-2 infection among patients using immunomodulatory therapies‏
670 ‎‡a  Author's Severe hypothermia in association with sodium valproate overdose‏
670 ‎‡a  Author's Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19‏
670 ‎‡a  Author's Systematic review of the prevalence of gout and hyperuricaemia in Australia.‏
670 ‎‡a  Author's The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward‏
670 ‎‡a  Author's The Cost-effectiveness of Biannual Serum Urate‏
670 ‎‡a  Author's The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring‏
670 ‎‡a  Author's The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic‏
670 ‎‡a  Author's The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice‏
670 ‎‡a  Author's The effect of reducing systemic inflammation on serum urate‏
670 ‎‡a  Author's The genetics of ankylosing spondylitis and axial spondyloarthritis‏
670 ‎‡a  Author's The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis‏
670 ‎‡a  Author's The management of gout: Much has changed‏
670 ‎‡a  Author's The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19‏
670 ‎‡a  Author's The prevalence of gout and hyperuricaemia in Australia: An updated systematic review‏
670 ‎‡a  Author's The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance‏
670 ‎‡a  Author's The window of opportunity: a relevant concept for axial spondyloarthritis‏
670 ‎‡a  Author's Time to recognise gout as a chronic disease‏
670 ‎‡a  Author's Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals‏
670 ‎‡a  Author's Venous thromboembolism in medical inpatients--the silent epidemic of neglect‏
670 ‎‡a  Author's Waiting for JAK inhibitor safety data‏
909 ‎‡a  (orcid) 0000000231563418‏ ‎‡9  1‏
912 ‎‡a  authorreply‏ ‎‡A  Author reply‏ ‎‡9  1‏
912 ‎‡a  gouthyperuricaemiaandcrystalassociateddiseasenetworkgcanconsensusstatementregardinglabelsanddefinitionsofdiseasestatesofgout‏ ‎‡A  Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout‏ ‎‡9  1‏
912 ‎‡a  identificationofmultipleriskvariantsforankylosingspondylitisthroughhighdensitygenotypingofimmunerelatedloci‏ ‎‡A  Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci‏ ‎‡9  1‏
919 ‎‡a  systematicreviewoftheinfectiouscomplicationsofcolchicineandtheuseofcolchicinetotreatinfections‏ ‎‡A  A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections‏ ‎‡9  1‏
919 ‎‡a  advancesinclassificationbasicmechanismsandclinicalscienceinankylosingspondylitisandaxialspondyloarthritis‏ ‎‡A  Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.‏ ‎‡9  1‏
919 ‎‡a  advancesinpharmacotherapyforthetreatmentofgout‏ ‎‡A  Advances in pharmacotherapy for the treatment of gout‏ ‎‡9  1‏
919 ‎‡a  adverseeventsduringoralcolchicineuseasystematicreviewandmetaanalysisofrandomisedcontrolledtrials‏ ‎‡A  Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials‏ ‎‡9  1‏
919 ‎‡a  observationalstudyofgoutprevalenceandqualityofcareinanationalaustraliangeneralpracticepopulation‏ ‎‡A  An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population‏ ‎‡9  1‏
919 ‎‡a  appropriatenessofantineutrophilcytoplasmicantibodytestinginatertiaryhospital‏ ‎‡A  Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital.‏ ‎‡9  1‏
919 ‎‡a  associationofcrohnsdiseaserelatedchromosome1q32withankylosingspondylitisisindependentofbowelsymptomsandfaecalcalprotectin‏ ‎‡A  Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin‏ ‎‡9  1‏
919 ‎‡a  axialspondyloarthritisanewdiseaseentitynotnecessarilyearlyankylosingspondylitis‏ ‎‡A  Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis‏ ‎‡9  1‏
919 ‎‡a  baselineuseofhydroxychloroquineinsystemiclupuserythematosusdoesnotprecludesarscov2infectionandseverecovid19‏ ‎‡A  Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19‏ ‎‡9  1‏
919 ‎‡a  biologictherapyforuveitisaddressingaccessissuesisparamount‏ ‎‡A  Biologic therapy for uveitis: addressing access issues is paramount‏ ‎‡9  1‏
919 ‎‡a  briefreportintestinaldysbiosisinankylosingspondylitis‏ ‎‡A  Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis‏ ‎‡9  1‏
919 ‎‡a  characteristicsassociatedwithhospitalisationforcovid19inpeoplewithrheumaticdiseasedatafromthecovid19globalrheumatologyalliancephysicianreportedregistry‏ ‎‡A  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry‏ ‎‡9  1‏
919 ‎‡a  classificationcriteriaperipheralspondyloarthropathyandpsoriaticarthritis‏ ‎‡A  Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis‏ ‎‡9  1‏
919 ‎‡a  colchicineprophylaxisofgoutflareswhencommencingallopurinolisverycosteffective‏ ‎‡A  Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol is Very Cost Effective‏ ‎‡9  1‏
919 ‎‡a  conductingresearchinapandemicthepowerofsocialmedia‏ ‎‡A  Conducting research in a pandemic: The power of social media‏ ‎‡9  1‏
919 ‎‡a  consensusstatementontheinvestigationandmanagementofnonradiographicaxialspondyloarthritisnraxspa‏ ‎‡A  Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).‏ ‎‡9  1‏
919 ‎‡a  consensusstatementsontheimagingofaxialspondyloarthritisinaustraliaandnewzealand‏ ‎‡A  Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand.‏ ‎‡9  1‏
919 ‎‡a  coronavirusdisease2019investigationaltherapiesinthepreventionandtreatmentofhyperinflammation‏ ‎‡A  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation‏ ‎‡9  1‏
919 ‎‡a  covid19globalrheumatologyallianceregistryantiil6therapyshareddecisionmakingandpatientoutcomesresponsetocorrespondenceoncharacteristicsassociatedwithhospitalisationforcovid19inpeoplewithrheumaticdiseasedatafrom‏ ‎‡A  COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from‏ ‎‡9  1‏
919 ‎‡a  covid19inpeoplewithrheumaticdiseasesrisksoutcomestreatmentconsiderations‏ ‎‡A  COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations‏ ‎‡9  1‏
919 ‎‡a  diffusionweightedimagingisasensitiveandspecificmagneticresonancesequenceinthediagnosisofankylosingspondylitis‏ ‎‡A  Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis‏ ‎‡9  1‏
919 ‎‡a  diseaseassociatedpolymorphismsinerap1donotalterendoplasmicreticulumstressinpatientswithankylosingspondylitis‏ ‎‡A  Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis‏ ‎‡9  1‏
919 ‎‡a  doesmidlifeobesityreallylowerdementiarisk‏ ‎‡A  Does midlife obesity really lower dementia risk?‏ ‎‡9  1‏
919 ‎‡a  endoplasmicreticulumaminopeptidasesinthepathogenesisofankylosingspondylitis‏ ‎‡A  Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis.‏ ‎‡9  1‏
919 ‎‡a  epidemiologyandoutcomesofnovelcoronavirus2019inpatientswithimmunemediatedinflammatorydiseases‏ ‎‡A  Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases‏ ‎‡9  1‏
919 ‎‡a  epidemiologyofinpatientgoutinaustraliaandnewzealandtemporaltrendscomorbiditiesandgoutflaresite‏ ‎‡A  Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site‏ ‎‡9  1‏
919 ‎‡a  erap1biologyandassessmentinankylosingspondylitis‏ ‎‡A  ERAP1 biology and assessment in Ankylosing Spondylitis.‏ ‎‡9  1‏
919 ‎‡a  erap2functionalknockoutinhumansdoesnotaltersurfaceheavychainsorhlab27inflammatorycytokinesorendoplasmicreticulumstressmarkers‏ ‎‡A  ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers‏ ‎‡9  1‏
919 ‎‡a  erap2isassociatedwithankylosingspondylitisinhlab27positiveandhlab27negativepatients‏ ‎‡A  ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients‏ ‎‡9  1‏
919 ‎‡a  evaluationoftheeffectofbaselinemrisacroiliitisand100reactiveproteinstatusonetanercepttreatmentresponseinnonradiographicaxialspondyloarthritisaposthocanalysisoftheembarkstudy‏ ‎‡A  Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study‏ ‎‡9  1‏
919 ‎‡a  exomewidestudyofankylosingspondylitisdemonstratesadditionalsharedgeneticbackgroundwithinflammatoryboweldisease‏ ‎‡A  Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease‏ ‎‡9  1‏
919 ‎‡a  factorsassociatedwithcovid19relateddeathinpeoplewithrheumaticdiseasesresultsfromthecovid19globalrheumatologyalliancephysicianreportedregistry‏ ‎‡A  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry‏ ‎‡9  1‏
919 ‎‡a  febuxostatforthetreatmentofhyperuricaemiaingout‏ ‎‡A  Febuxostat for the treatment of hyperuricaemia in gout‏ ‎‡9  1‏
919 ‎‡a  festinalentehydroxychloroquinecovid19andtheroleoftherheumatologist‏ ‎‡A  Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist‏ ‎‡9  1‏
919 ‎‡a  geneticdiagnosticprofilinginaxialspondyloarthritisarealworldstudy‏ ‎‡A  Genetic diagnostic profiling in axial spondyloarthritis: a real world study‏ ‎‡9  1‏
919 ‎‡a  geneticdissectionofacuteanterioruveitisrevealssimilaritiesanddifferencesinassociationsobservedwithankylosingspondylitis‏ ‎‡A  Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis‏ ‎‡9  1‏
919 ‎‡a  geneticsofankylosingspondylitis‏ ‎‡A  Genetics of ankylosing spondylitis‏ ‎‡9  1‏
919 ‎‡a  genomewideassociationstudyofacuteanterioruveitisidentifiesnewsusceptibilityloci‏ ‎‡A  Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci‏ ‎‡9  1‏
919 ‎‡a  giantcellarteritisandcovid19similaritiesanddiscriminatorsasystematicliteraturereview‏ ‎‡A  Giant cell arteritis and COVID-19: similarities and discriminators, a systematic literature review‏ ‎‡9  1‏
919 ‎‡a  globalresearchcollaborationinapandemicchallengesandopportunitiesthecovid19globalrheumatologyalliance‏ ‎‡A  Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance‏ ‎‡9  1‏
919 ‎‡a  goutanupdateofaetiologygeneticscomorbiditiesandmanagement‏ ‎‡A  Gout - An update of aetiology, genetics, co-morbidities and management‏ ‎‡9  1‏
919 ‎‡a  gouthyperuricemiaandcrystalassociateddiseasenetworkconsensusstatementregardinglabelsanddefinitionsfordiseaseelementsingout‏ ‎‡A  Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout‏ ‎‡9  1‏
919 ‎‡a  goutjointsandbeyondepidemiologyclinicalfeaturestreatmentandcomorbidities‏ ‎‡A  Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.‏ ‎‡9  1‏
919 ‎‡a  goutrheumatoidarthritisandtheriskofdeathrelatedtocoronavirusdisease2019ananalysisoftheukbiobank‏ ‎‡A  Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank‏ ‎‡9  1‏
919 ‎‡a  hospitaladmissionsassociatedwithgoutandtheircomorbiditiesinnewzealandandengland1999‏ ‎‡A  Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.‏ ‎‡9  1‏
919 ‎‡a  insightintorheumatologicalcauseandeffectthroughtheuseofmendelianrandomization‏ ‎‡A  Insight into rheumatological cause and effect through the use of Mendelian randomization‏ ‎‡9  1‏
919 ‎‡a  lesinuradforthetreatmentofhyperuricaemiainpeoplewithgout‏ ‎‡A  Lesinurad for the treatment of hyperuricaemia in people with gout‏ ‎‡9  1‏
919 ‎‡a  majorhistocompatibilitycomplexassociationsofankylosingspondylitisarecomplexandinvolvefurtherepistasiswitherap1‏ ‎‡A  Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.‏ ‎‡9  1‏
919 ‎‡a  managementofautoimmunediseaseduringthecovid19pandemic‏ ‎‡A  Management of autoimmune disease during the COVID-19 pandemic‏ ‎‡9  1‏
919 ‎‡a  managementofpatientswithgoutandachievementoftargetserumuratelevelsatatertiaryrheumatologyserviceinaustralia‏ ‎‡A  Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia‏ ‎‡9  1‏
919 ‎‡a  nevertoooldforaninheritedcondition‏ ‎‡A  Never too old for an inherited condition‏ ‎‡9  1‏
919 ‎‡a  nonradiographicaxialspondyloarthritisnraxspaadvancesinclassificationimagingandtherapy‏ ‎‡A  Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy‏ ‎‡9  1‏
919 ‎‡a  novelcoronavirusdisease2019covid19inpeoplewithrheumaticdiseaseepidemiologyandoutcomes‏ ‎‡A  Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes‏ ‎‡9  1‏
919 ‎‡a  patientswithsystemiclupuserythematosususinghydroxychloroquineorchloroquinedevelopseverecovid19atsimilarfrequencyaspatientsnotonantimalarialsneedtoexploreantithromboticbenefitsforcovid19coagulopathyresponsetoclinic‏ ‎‡A  Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinic‏ ‎‡9  1‏
919 ‎‡a  poorcompliancewithcommunityacquiredpneumoniaantibioticguidelinesinalargeaustralianprivatehospitalemergencydepartment‏ ‎‡A  Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department‏ ‎‡9  1‏
919 ‎‡a  predictorsofsuccessingouttreatment‏ ‎‡A  Predictors of Success in Gout Treatment‏ ‎‡9  1‏
919 ‎‡a  raceethnicityassociationwithcovid19outcomesinrheumaticdiseasedatafromthecovid19globalrheumatologyalliancephysicianregistry‏ ‎‡A  Race/ethnicity association with COVID-19 outcomes in rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician Registry‏ ‎‡9  1‏
919 ‎‡a  responsetoglucocorticoidinducedrelapseofcovid19inapatientwithsarcoidosisbygyorfietal‏ ‎‡A  Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al‏ ‎‡9  1‏
919 ‎‡a  rheumaticdiseaseactivityglucocorticoiduseandcovid19responsetocommentoncharacteristicsassociatedwithhospitalisationforcovid19inpeoplewithrheumaticdiseasedatafromthecovid19globalrheumatologyalliancephysicianrepor‏ ‎‡A  Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-repor‏ ‎‡9  1‏
919 ‎‡a  rheumaticdiseaseandcovid19initialdatafromthecovid19globalrheumatologyallianceproviderregistries‏ ‎‡A  Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries‏ ‎‡9  1‏
919 ‎‡a  roleofgeneticsininfectionassociatedarthritis‏ ‎‡A  Role of genetics in infection-associated arthritis‏ ‎‡9  1‏
919 ‎‡a  rothiaaeriaasacauseofsepsisinanativejoint‏ ‎‡A  Rothia aeria as a cause of sepsis in a native joint‏ ‎‡9  1‏
919 ‎‡a  sarscov2infectionamongpatientsusingimmunomodulatorytherapies‏ ‎‡A  SARS CoV-2 infection among patients using immunomodulatory therapies‏ ‎‡9  1‏
919 ‎‡a  severehypothermiainassociationwithsodiumvalproateoverdose‏ ‎‡A  Severe hypothermia in association with sodium valproate overdose‏ ‎‡9  1‏
919 ‎‡a  swingingthependulumlessonslearnedfrompublicdiscourseconcerninghydroxychloroquineandcovid19‏ ‎‡A  Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19‏ ‎‡9  1‏
919 ‎‡a  systematicreviewoftheprevalenceofgoutandhyperuricaemiainaustralia‏ ‎‡A  Systematic review of the prevalence of gout and hyperuricaemia in Australia.‏ ‎‡9  1‏
919 ‎‡a  asascriteriaforaxialspondyloarthritisstrengthsweaknessesandproposalsforawayforward‏ ‎‡A  The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward‏ ‎‡9  1‏
919 ‎‡a  costeffectivenessofbiannualserumurate‏ ‎‡A  The Cost-effectiveness of Biannual Serum Urate‏ ‎‡9  1‏
919 ‎‡a  costeffectivenessofbiannualserumuratesumonitoringafterreachingtargetingoutahealtheconomicanalysiscomparingsumonitoring‏ ‎‡A  The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring‏ ‎‡9  1‏
919 ‎‡a  covid19globalrheumatologyalliancecollectingdatainapandemic‏ ‎‡A  The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic‏ ‎‡9  1‏
919 ‎‡a  covid19globalrheumatologyallianceevaluatingtherapiddesignandimplementationofaninternationalregistryagainstbestpractice‏ ‎‡A  The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice‏ ‎‡9  1‏
919 ‎‡a  effectofreducingsystemicinflammationonserumurate‏ ‎‡A  The effect of reducing systemic inflammation on serum urate‏ ‎‡9  1‏
919 ‎‡a  geneticsofankylosingspondylitisandaxialspondyloarthritis‏ ‎‡A  The genetics of ankylosing spondylitis and axial spondyloarthritis‏ ‎‡9  1‏
919 ‎‡a  intestinalmicrobiomeinhumandiseaseandhowitrelatestoarthritisandspondyloarthritis‏ ‎‡A  The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis‏ ‎‡9  1‏
919 ‎‡a  managementofgoutmuchhaschanged‏ ‎‡A  The management of gout: Much has changed‏ ‎‡9  1‏
919 ‎‡a  potentialforrepurposingantitnfasatherapyforthetreatmentofcovid19‏ ‎‡A  The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19‏ ‎‡9  1‏
919 ‎‡a  prevalenceofgoutandhyperuricaemiainaustraliaanupdatedsystematicreview‏ ‎‡A  The prevalence of gout and hyperuricaemia in Australia: An updated systematic review‏ ‎‡9  1‏
919 ‎‡a  rheumatologycommunityrespondstothecovid19pandemictheestablishmentofthecovid19globalrheumatologyalliance‏ ‎‡A  The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance‏ ‎‡9  1‏
919 ‎‡a  windowofopportunityarelevantconceptforaxialspondyloarthritis‏ ‎‡A  The window of opportunity: a relevant concept for axial spondyloarthritis‏ ‎‡9  1‏
919 ‎‡a  timetorecognisegoutasachronicdisease‏ ‎‡A  Time to recognise gout as a chronic disease‏ ‎‡9  1‏
919 ‎‡a  timetotreatmentinrheumatoidarthritisfactorsassociatedwithtimetotreatmentinitiationandurgenttriageassessmentofgeneralpractitionerreferrals‏ ‎‡A  Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals‏ ‎‡9  1‏
919 ‎‡a  venousthromboembolisminmedicalinpatientsthesilentepidemicofneglect‏ ‎‡A  Venous thromboembolism in medical inpatients--the silent epidemic of neglect‏ ‎‡9  1‏
919 ‎‡a  waitingforjakinhibitorsafetydata‏ ‎‡A  Waiting for JAK inhibitor safety data‏ ‎‡9  1‏
919 ‎‡a  accumulatingevidencesuggestsantitnftherapyneedstobegiventrialpriorityincovid19treatment‏ ‎‡A  Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticsinformedapproachtonavigatinghydroxychloroquineshortagesinpatientswithrheumaticdiseaseduringthecovid19pandemic‏ ‎‡A  A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic‏ ‎‡9  1‏
919 ‎‡a  qualitativeandquantitativeanalysisofthecharacteristicsofgoutpatienteducationresources‏ ‎‡A  A qualitative and quantitative analysis of the characteristics of gout patient education resources‏ ‎‡9  1‏
943 ‎‡a  200x‏ ‎‡A  2009‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000387041843‏
996 ‎‡2  SIMACOB|22906979‏
996 ‎‡2  PLWABN|9810670480405606‏
996 ‎‡2  BIBSYS|90685671‏
996 ‎‡2  BIBSYS|12046540‏
996 ‎‡2  ISNI|0000000395392707‏
996 ‎‡2  J9U|987007424725505171‏
996 ‎‡2  BNC|981058609025406706‏
996 ‎‡2  SIMACOB|7219811‏
996 ‎‡2  BIBSYS|90920247‏
996 ‎‡2  LC|no 99022121‏
996 ‎‡2  DBC|87097948918417‏
996 ‎‡2  BNF|14132645‏
996 ‎‡2  ISNI|0000000030966253‏
996 ‎‡2  LC|n 2010185059‏
996 ‎‡2  ISNI|0000000028706807‏
996 ‎‡2  LC|n 89672291‏
996 ‎‡2  BNF|12498886‏
996 ‎‡2  RERO|A011484104‏
996 ‎‡2  BIBSYS|90393357‏
996 ‎‡2  SUDOC|111716314‏
996 ‎‡2  DBC|87097969668194‏
996 ‎‡2  BIBSYS|90268423‏
996 ‎‡2  N6I|vtls001380620‏
996 ‎‡2  LC|no2011090638‏
996 ‎‡2  ISNI|0000000067244289‏
996 ‎‡2  NII|DA03788112‏
996 ‎‡2  LC|n 84028876‏
996 ‎‡2  NKC|xx0201986‏
996 ‎‡2  NTA|24297841X‏
996 ‎‡2  BNF|12500126‏
996 ‎‡2  DNB|1078141444‏
996 ‎‡2  NDL|00744776‏
996 ‎‡2  NTA|072425563‏
996 ‎‡2  J9U|987007436558905171‏
996 ‎‡2  ISNI|0000000109593277‏
996 ‎‡2  DNB|141930241‏
996 ‎‡2  BNF|13072683‏
996 ‎‡2  LC|no2008130075‏
996 ‎‡2  SUDOC|257796770‏
996 ‎‡2  ISNI|0000000433802253‏
996 ‎‡2  J9U|987007449410705171‏
996 ‎‡2  ISNI|0000000081691077‏
996 ‎‡2  RERO|A009361512‏
996 ‎‡2  LIH|LNB:BE_i__g_;=B_n_‏
996 ‎‡2  NUKAT|n 98007492‏
996 ‎‡2  ISNI|000000012277243X‏
996 ‎‡2  J9U|987007281045705171‏
996 ‎‡2  DBC|87097969668208‏
996 ‎‡2  DNB|122216946‏
996 ‎‡2  BNE|XX1596941‏
996 ‎‡2  NTA|068283520‏
996 ‎‡2  NTA|068217749‏
996 ‎‡2  RERO|A003752233‏
996 ‎‡2  DNB|1157227031‏
996 ‎‡2  SUDOC|095159304‏
996 ‎‡2  NLA|000035457257‏
996 ‎‡2  DNB|129577243‏
996 ‎‡2  LC|no 96027255‏
996 ‎‡2  LC|nb2011015484‏
996 ‎‡2  LC|n 89621570‏
996 ‎‡2  BIBSYS|90107897‏
996 ‎‡2  ISNI|0000000039443299‏
996 ‎‡2  SUDOC|171183495‏
996 ‎‡2  ISNI|0000000421093939‏
996 ‎‡2  LC|n 2012069387‏
996 ‎‡2  LC|no2016044946‏
996 ‎‡2  BIBSYS|90563567‏
996 ‎‡2  NUKAT|n 98085257‏
996 ‎‡2  SZ|122216946‏
996 ‎‡2  ISNI|0000000499934267‏
996 ‎‡2  CAOONL|ncf11585405‏
996 ‎‡2  LC|no2018172862‏
996 ‎‡2  PTBNP|1075323‏
996 ‎‡2  PLWABN|9810590929405606‏
996 ‎‡2  BNF|15071814‏
996 ‎‡2  NKC|mub2013766629‏
996 ‎‡2  CAOONL|ncf10083939‏
996 ‎‡2  NLA|000036004296‏
996 ‎‡2  NII|DA0821577X‏
996 ‎‡2  LC|nb2002064415‏
996 ‎‡2  BIBSYS|90945226‏
996 ‎‡2  LC|n 83208325‏
996 ‎‡2  NTA|283600128‏
996 ‎‡2  NTA|073432520‏
996 ‎‡2  NUKAT|n 2005018713‏
996 ‎‡2  LC|nb2016021802‏
996 ‎‡2  SUDOC|119356945‏
996 ‎‡2  SIMACOB|418840835‏
996 ‎‡2  BIBSYS|90652323‏
996 ‎‡2  BIBSYS|90185694‏
996 ‎‡2  DNB|122218248‏
996 ‎‡2  J9U|987007350857105171‏
996 ‎‡2  BNF|15798320‏
996 ‎‡2  RERO|A024299684‏
996 ‎‡2  NTA|072091479‏
996 ‎‡2  DNB|1193151384‏
996 ‎‡2  J9U|987007267157405171‏
996 ‎‡2  ISNI|0000000024316668‏
996 ‎‡2  BIBSYS|98039773‏
996 ‎‡2  LC|nb2023015504‏
996 ‎‡2  DE633|pe30028786‏
996 ‎‡2  NII|DA10164117‏
996 ‎‡2  LNB|LNC10-000145728‏
996 ‎‡2  NUKAT|n 2016005147‏
996 ‎‡2  LC|no2008167742‏
996 ‎‡2  SUDOC|034208844‏
996 ‎‡2  LC|no2009077612‏
996 ‎‡2  NII|DA06391421‏
996 ‎‡2  BNE|XX1005540‏
996 ‎‡2  SUDOC|248214306‏
996 ‎‡2  SUDOC|23780381X‏
996 ‎‡2  ISNI|0000000114196719‏
996 ‎‡2  SUDOC|257615709‏
996 ‎‡2  LC|nb2008000818‏
996 ‎‡2  ISNI|0000000383052705‏
996 ‎‡2  SUDOC|16221250X‏
996 ‎‡2  BNC|981058514131506706‏
996 ‎‡2  ISNI|0000000120474316‏
996 ‎‡2  LNB|LNC10-000033723‏
996 ‎‡2  NII|DA00828968‏
996 ‎‡2  SUDOC|24078314X‏
996 ‎‡2  ISNI|0000000060137245‏
996 ‎‡2  SUDOC|167705318‏
996 ‎‡2  LC|nb2019000596‏
996 ‎‡2  LC|n 91063924‏
996 ‎‡2  J9U|987007458311905171‏
996 ‎‡2  DNB|1165157950‏
996 ‎‡2  ISNI|0000000453516377‏
996 ‎‡2  SIMACOB|16593763‏
996 ‎‡2  BNF|16945031‏
996 ‎‡2  BNE|XX978993‏
996 ‎‡2  ISNI|0000000121397754‏
996 ‎‡2  NTA|071947930‏
996 ‎‡2  ISNI|000000004347360X‏
996 ‎‡2  RERO|A012381098‏
996 ‎‡2  N6I|vtls001339002‏
996 ‎‡2  DNB|1146270356‏
996 ‎‡2  CAOONL|ncf11173551‏
996 ‎‡2  LC|n 81134909‏
996 ‎‡2  J9U|987007447078505171‏
996 ‎‡2  BIBSYS|90093057‏
996 ‎‡2  SUDOC|139421211‏
996 ‎‡2  LC|no2003100051‏
996 ‎‡2  LC|n 89638386‏
996 ‎‡2  NII|DA05533597‏
996 ‎‡2  BIBSYS|90503076‏
996 ‎‡2  SIMACOB|161784419‏
996 ‎‡2  ISNI|0000000054131162‏
996 ‎‡2  SUDOC|081069677‏
996 ‎‡2  SIMACOB|229047139‏
996 ‎‡2  LC|n 88056718‏
996 ‎‡2  ISNI|0000000106775016‏
996 ‎‡2  ISNI|000000043493643X‏
996 ‎‡2  LC|no2019169642‏
996 ‎‡2  RERO|A003752235‏
996 ‎‡2  RERO|A012332750‏
996 ‎‡2  RERO|A025500390‏
996 ‎‡2  NDL|00956843‏
996 ‎‡2  RERO|A010141671‏
996 ‎‡2  NII|DA03814234‏
996 ‎‡2  LC|no2015012247‏
996 ‎‡2  ISNI|0000000496479975‏
996 ‎‡2  SIMACOB|418849027‏
996 ‎‡2  CAOONL|ncf10134451‏
996 ‎‡2  LC|no 95058483‏
996 ‎‡2  SZ|1165157950‏
996 ‎‡2  ISNI|0000000398683198‏
996 ‎‡2  ISNI|0000000110578015‏
996 ‎‡2  BIBSYS|90268848‏
996 ‎‡2  ISNI|0000000425497842‏
996 ‎‡2  LC|nb2011019978‏
996 ‎‡2  NYNYRILM|175703‏
996 ‎‡2  NUKAT|n 2020210662‏
996 ‎‡2  LC|n 96065043‏
996 ‎‡2  LC|no2022114969‏
996 ‎‡2  SUDOC|167726927‏
996 ‎‡2  LC|n 92027545‏
996 ‎‡2  BIBSYS|1054071‏
996 ‎‡2  NUKAT|n 2019157649‏
996 ‎‡2  ISNI|0000000050867930‏
996 ‎‡2  PTBNP|231789‏
996 ‎‡2  NUKAT|n 2016084279‏
996 ‎‡2  BNE|XX4934829‏
996 ‎‡2  NTA|074525689‏
996 ‎‡2  LC|n 90690308‏
996 ‎‡2  LC|n 84217486‏
996 ‎‡2  J9U|987007456527105171‏
996 ‎‡2  BNF|15595696‏
996 ‎‡2  SIMACOB|299486051‏
996 ‎‡2  LC|n 88184392‏
996 ‎‡2  LC|nb2005014799‏
996 ‎‡2  LC|n 2014020261‏
996 ‎‡2  ISNI|0000000023570445‏
996 ‎‡2  ISNI|000000010999912X‏
996 ‎‡2  BIBSYS|90116051‏
996 ‎‡2  LC|no 99022107‏
996 ‎‡2  ISNI|0000000108218942‏
996 ‎‡2  SIMACOB|100024419‏
996 ‎‡2  ISNI|0000000041267239‏
996 ‎‡2  ISNI|0000000108586614‏
996 ‎‡2  RERO|A003752217‏
996 ‎‡2  SUDOC|188177728‏
996 ‎‡2  RERO|A021517853‏
996 ‎‡2  PLWABN|9810695779605606‏
996 ‎‡2  J9U|987007350722405171‏
996 ‎‡2  J9U|987007361869605171‏
996 ‎‡2  LC|nb 97066186‏
996 ‎‡2  NSK|000103522‏
996 ‎‡2  DNB|12221837X‏
996 ‎‡2  SUDOC|255366779‏
996 ‎‡2  SUDOC|254339077‏
996 ‎‡2  LC|n 81095592‏
996 ‎‡2  BIBSYS|90132221‏
996 ‎‡2  ISNI|0000000037025667‏
996 ‎‡2  NKC|xx0040136‏
996 ‎‡2  ISNI|0000000120452790‏
996 ‎‡2  ISNI|0000000078258125‏
996 ‎‡2  NII|DA07003302‏
996 ‎‡2  LC|n 2004002915‏
996 ‎‡2  BLBNB|000334852‏
996 ‎‡2  NTA|071776710‏
996 ‎‡2  BLBNB|000334856‏
996 ‎‡2  BIBSYS|90239843‏
996 ‎‡2  LC|n 83229391‏
996 ‎‡2  N6I|vtls000042579‏
996 ‎‡2  BIBSYS|90630075‏
996 ‎‡2  J9U|987007373539105171‏
996 ‎‡2  LC|nb2003022262‏
996 ‎‡2  SUDOC|069511748‏
996 ‎‡2  SUDOC|078680913‏
996 ‎‡2  DNB|1341102440‏
996 ‎‡2  LC|n 81134908‏
996 ‎‡2  CAOONL|ncf11327372‏
996 ‎‡2  ISNI|000000003929406X‏
996 ‎‡2  SUDOC|270794107‏
996 ‎‡2  NII|DA13775525‏
996 ‎‡2  PLWABN|9810544269105606‏
996 ‎‡2  DNB|1136632131‏
996 ‎‡2  ISNI|0000000053567060‏
996 ‎‡2  BAV|495_373499‏
996 ‎‡2  NTA|315485310‏
996 ‎‡2  NKC|xx0114041‏
996 ‎‡2  DNB|122223888‏
996 ‎‡2  SUDOC|261205544‏
996 ‎‡2  BIBSYS|12053921‏
996 ‎‡2  NII|DA19248522‏
996 ‎‡2  RERO|A021510948‏
996 ‎‡2  NUKAT|n 93081272‏
996 ‎‡2  LIH|LNB:B9U_a_;=BX‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏
998 ‎‡a  Robinson, Philip‏ ‎‡2  ISNI|0000000110578015‏ ‎‡3  exact name‏
998 ‎‡a  Robinson, Philip‏ ‎‡2  ISNI|0000000110578015‏ ‎‡3  exact name‏
998 ‎‡a  Philip Robinson‏ ‎‡2  ISNI|0000000110578015‏ ‎‡3  exact name‏